跳至主要内容
临床试验/NL-OMON36274
NL-OMON36274已完成不适用

Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure - DEFEAT-HF

Medtronic Trading NL BV0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • LVEF of 35% or less
  • NYHA functional Class III
  • QRS duration less than 120 ms
  • LVEDD of 55 mm - 80 mm
  • Receiving stable medical therapy for heart failure prior to enrollment.

排除标准

  • Temporal stop of anticoagulation therapy poses an unacceptable health risk
  • Inability to perform an exercise capacity test
  • Pregnancy or likely to get pregant during the course of the study
  • CABG/PCI/BMS procedures within the past 90 days
  • Heart transplant
  • Acute Coronary Syndrome within the past 90 days
  • Congenital heart disease with significant hemodynamic shunting
  • Reversible cardiomyopathy (i.e. tachycardia induced heart failure)
  • Diagnosed unstable angina pectoris
  • Unstable coronary artery disease
  • CRT device implanted
  • non-Medtronic ICD, pacemaker or defibrillation lead
  • Patient already has a neurostimulator
  • (see p15-16)

研究者

发起方
Medtronic Trading NL BV

相似试验